Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06504446 | Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough | PHASE2 | RECRUITING | 455 | — | — | Sep 24, 2024 | Apr 10, 2026 | Feb 17, 2026 | 107 | United States, Belgium +4 |
Change in 24-hour Coughs per hour from Baseline will be based on VitaloJAK® Cough Counts. The VitaloJAK® is a 510(k)-cleared medical device consisting of a digital sound recorder with 2 microphones; a lapel air microphone attached to the participant's clothing and an adhesive chest wall microphone which is attached to the skin at the top of the sternum.
| Arm | Type | Description |
|---|---|---|
| NOC-110 1mg | EXPERIMENTAL | NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler. |
| NOC-110 3mg | EXPERIMENTAL | NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler. |
| NOC-110 6mg | EXPERIMENTAL | NOC-110 (taplucainium) administered by daily dry powder inhalation. NOC-110 contains a dry powder lactose blend containing drug substance taplucainium administered using an available inhaler. |
| Placebo | PLACEBO_COMPARATOR | The matching placebo contains inhalation grade lactose blended with arginine. The blend is taste masked to the active drug product to minimize unblinding due to taste differences. The matching placebo will be administered via the same inhaler. |
| Name | Type | Description |
|---|---|---|
| NOC-110 | DRUG | Inhalation powder |
| Placebo | OTHER | Inhalation powder |
Inclusion Criteria: * Refractory or unexplained chronic cough for ≥ 12 months. * Women of childbearing potential agree to follow the protocol specified contraceptive - guidance during the study. * Males who are not vasectomized must agree to use the contraceptive methods defined in the protocol. * ...